Kratko priopćenje
https://doi.org/10.20471/may.2022.58.02.14
Daridorexant
Vjekoslav Peitl
orcid.org/0000-0003-4163-6411
; Department of Psychiatry, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia; School of Medicine, Catholic University of Croatia, Zagreb, Croatia
Darko Vlahović
; Department of Psychiatry, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia
Sažetak
Daridorexant belongs to a class of drugs known as dual orexin receptor (OX1R and OX2R) antagonists. It achieves its function by blocking the binding of wake-promoting neuropeptides orexins. This novel mechanism is believed to turn down overactive wakefulness and as we know so far, most other treatments for insomnia can be sedating.
Ključne riječi
Hrčak ID:
284581
URI
Datum izdavanja:
23.10.2022.
Posjeta: 790 *